New Findings from Yonsei University College of Medicine in the Area of Thyroid Cancer Described (New Small-Molecule SERCA Inhibitors Enhance Treatment Efficacy in Lenvatinib-Resistant Papillary Thyroid Cancer).

A recent study from Yonsei University College of Medicine in Seoul, South Korea, focused on enhancing treatment efficacy in lenvatinib-resistant papillary thyroid cancer. The research aimed to identify small-molecule SERCA inhibitors to target drug-resistant cancers effectively. The study found that two SERCA inhibitors showed promise in reducing cell viability in patient-derived lenvatinib-resistant PTC cells when used in combination with lenvatinib, offering potential clinical value for new combination therapies. The findings were published in the International Journal of Molecular Sciences. [Extracted from the article]